Global Health Limited
Global Health Limited, together with its subsidiaries, provides healthcare services in India. The company offers treatments in the areas of digestive and hepatobiliary sciences, cardiac and cancer care, neurosciences, gastrosciences, orthopaedics, renal care, liver transplant, lung transplant, bone marrow transplant, chest surgery, gynaecology and gynaeoncology, paediatric care, obstetrics, emergency, ENT, head and neck surgery, internal medicine, respiratory and sleep medicine, peripheral vascular and endovascular sciences, endocrinology and diabetes, rheumatology and immunology, radiology and imaging, ophthalmology, critical care, dermatology, dentistry, and dietetics and nutrition, as well as plastic, aesthetic, and reconstructive surgery. It also provides second opinion, lab tests and diagnostics, homecare and elder care services, telemedicine and air ambulance services, and e-ICU services, and health plans checkup. In addition, the company is involved in trading of pharmacy and other medical consumables; and medical and healthcare education activities. The company operates a network of hospitals under the Medanta brand. Global Health Limited was incorporated in 2004 and is based in Gurugram, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Strong 5-year revenue CAGR of 15.1%
Concerns1
- Negative free cash flow (βΉ205 Cr)
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 9 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ3.20 K Cr | β | βΉ462.00 Cr | β | β | 13.2% | 7.7% | -4.9% |
| Mar 2024 | βΉ2.98 K Cr | β | βΉ486.00 Cr | β | β | 16.0% | 50.7% | 84.8% |
| Mar 2023 | βΉ1.97 K Cr | β | βΉ263.00 Cr | β | β | 10.6% | 11.8% | 20.1% |
| Mar 2022 | βΉ1.76 K Cr | β | βΉ219.00 Cr | β | β | 12.6% | 43.8% | 284.2% |
| Mar 2021 | βΉ1.23 K Cr | β | βΉ57.00 Cr | β | β | 3.8% | -16.6% | -44.7% |
| Mar 2020 | βΉ1.47 K Cr | β | βΉ103.00 Cr | β | β | 7.4% | 2.2% | 63.5% |
| Mar 2019 | βΉ1.44 K Cr | β | βΉ63.00 Cr | β | β | 4.9% | 7.3% | 70.3% |
| Mar 2018 | βΉ1.34 K Cr | β | βΉ37.00 Cr | β | β | 3.1% | 5.2% | -31.5% |
| Mar 2017 | βΉ1.28 K Cr | β | βΉ54.00 Cr | β | β | 4.8% | β | β |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 3,424 |
| Total Expenses | 2,640 |
| EBIT / Operating Profit | 784 |
| OPM % | 23% |
| Other Income | 77 |
| Finance Costs | 30 |
| Depreciation & Amortisation | 146 |
| Profit Before Tax | 684 |
| Tax % | - |
| Net Profit / PAT | 517 |
| EPS (βΉ) | 19.24 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Global Health Limitedthis co. | βΉ31.40 K Cr | βΉ3.20 K Cr | 59.80 | 8.28 | 37.31 | 7.7% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |